Athersys (NASDAQ: ATHX) is a fully integrated pre-clinical, product discovery and development company with multiple synthetic pharmaceutical programs focused on obesity, cognition and other CNS disorders and asthma. The company also has a major effort in regenerative medicine (cell therapy). Using its MultiStemâ„¢ platform (Multipotent Adult Progenitor Cells), the company has multiple programs focused on cardiovascular disease, neurology, hematological and immune disorders and a range of other indications.

News: Athersys Extends Agreement with Healios, Receives $2 Million